Point of care blood eosinophil guided oral prednisolone for COPD exacerbations: a multi-centre double blind randomised controlled trial (The STARR2 trial)
Sanjay Ramakrishnan(The University of Western Australia), M Bafadhel(King's College London), R E Russell(University of Oxford), Shelley Bright, R Fox(Bicester Community Hospital), J Davies(University of Oxford), I Binnian(London Eye Hospital), C A'Court(Western Health and Social Care Trust), H Jeffers(University of Oxford), M Mahdi(University of Oxford), S Cartwright(Horse Hospital), B Langford-Wiley(University of Oxford)
Cited by 8
Related Papers
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
|The Lancet|2021|310
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
|Thorax|2021|169
Survival analysis of patients on maintenance hemodialysis
|Indian Journal of Nephrology|2014|100
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
|The Lancet Respiratory Medicine|2024|98